MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does MetaVia Inc. (MTVA) operate in?
MetaVia Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is MetaVia Inc. (MTVA) current stock price?
As of the latest data, MetaVia Inc. stock price is $1.49, with a previous close of $1.46. MetaVia Inc. gained $0.03 in the last trading session, representing a 2.05% increase.
What is MetaVia Inc. (MTVA) current market capitalization?
MetaVia Inc. market cap is approximately 7.69 million.
What is MetaVia Inc. (MTVA) Earnings Per Share (EPS)?
The trailing EPS is -$2.34, and the forward EPS is -$2.41.
What is MetaVia Inc. (MTVA) EBITDA?
MetaVia Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.38 million.
Does MetaVia Inc. (MTVA) pay dividends?
No. MetaVia Inc. does not pay a dividend.
What is MetaVia Inc. (MTVA) beta (volatility) score?
MetaVia Inc. has a beta of 0.903, meaning its volatility is roughly in line with the market.
